Merck

China’s cost and efficiency advantages in drug development have been recognised at the world’s largest cancer research conference in the…

Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a…

Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in Hong Kong,…

Shares of Chinese cancer drug developer Akeso slumped on Monday despite the company receiving a second marketing approval from the…